Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$135.29−21.27 (-13.59%)
Close on Nov 12, 2026Market cap $5.65BP/E –Yield –
Veradermics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Veradermics's EPS for the twelve months ending Sep 30, 2026 was -$40.02. For fiscal 2025 it was -$111.91.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$111.91 | – |
| FY2024 | Dec 31, 2024 | -$37.05 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.50 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.58 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.32 | – |
| Q4 FY2025 | Dec 31, 2025 | -$37.62 | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.15 | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.19 | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.79 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?